Draft Guidance on Naproxen

Active Ingredient: Naproxen

Dosage Form; Route: Suspension; oral

Recommended Studies: Two studies

1. Type of study: Fasting
   Design: Single-dose, two-treatment, two-period crossover in vivo
   Strength: 25 mg/mL
   Subjects: Males and non-pregnant, non-lactating females, general population
   Additional comments: None

2. Type of study: Fed
   Design: Single-dose, two-treatment, two-period crossover in vivo
   Strength: 25 mg/mL
   Subjects: Males and non-pregnant, non-lactating females, general population
   Additional comments: None

Analytes to measure (in appropriate biological fluid): Naproxen in plasma

Bioequivalence based on (90% CI): Naproxen

Waiver request of in vivo testing: Not applicable

Dissolution test method and sampling times: The dissolution information for this drug product can be found on the FDA-Recommended Dissolution Methods website, available to the public at the following location: http://www.accessdata.fda.gov/scripts/cder/dissolution/. Conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Note that a dosage unit is based on the labeled concentration of the suspension product. Use the dosage unit (1 ml). Specifications will be determined upon review of the abbreviated new drug application (ANDA).

Recommended May 2019